You are here

vaccines

Sinopharm shares phase 2 data on inactivated COVID-19 vaccine

Sinopharm shares phase 2 data on inactivated COVID-19 vaccine

Fierce Biotech

clinical trials

Flag link:

COVID-19 vaccines won't have a copay, HHS says

COVID-19 vaccines won't have a copay, HHS says

Beckers Hospital Review

Flag link:

CureVac grabs $213M in US IPO, adding to year's record pace

CureVac grabs $213M in US IPO, adding to year's record pace

BioPharma Dive

Flag link:

On heels of U.S. pact, Johnson & Johnson strikes a double-size COVID vaccine deal with Europe

On heels of U.S. pact, Johnson & Johnson strikes a double-size COVID vaccine deal with Europe

Fierce Pharma

Flag link:

Clinical Transparency Proponents Question Safety and Efficacy of Russia’s COVID-19 Vaccine

Clinical Transparency Proponents Question Safety and Efficacy of Russia’s COVID-19 Vaccine

BioSpace

Flag link:

COVID-19 vaccine players will split $100B in sales and $40B in profits, with Moderna leading the way: analyst

COVID-19 vaccine players will split $100B in sales and $40B in profits, with Moderna leading the way: analyst

Fierce Pharma

Moderna Therapeutics

Flag link:

AstraZeneca will work with Mexico, Argentina to produce COVID-19 vaccine doses: report

AstraZeneca will work with Mexico, Argentina to produce COVID-19 vaccine doses: report

Fierce Pharma

Flag link:

CanSino reaps $748M windfall from Shanghai IPO — as it warns Covid-19 vaccine won't be a huge money maker

CanSino reaps $748M windfall from Shanghai IPO — as it warns Covid-19 vaccine won't be a huge money maker

Endpoints

Flag link:

Anger at US deal for Moderna’s ‘taxpayer-funded’ COVID-19 vaccine

Anger at US deal for Moderna’s ‘taxpayer-funded’ COVID-19 vaccine

Pharmaforum

Moderna Therapeutics

Flag link:

Goldman Predicts ‘At Least One’ Vaccine Approval Before The End Of 2020, Raises GDP Estimate

Goldman Predicts ‘At Least One’ Vaccine Approval Before The End Of 2020, Raises GDP Estimate

Forbes

Flag link:

Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political

Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political

Xconomy

drug development

Flag link:

BioNTech and Pfizer Hope to Have Late-Stage Coronavirus Vaccine Results by October

BioNTech and Pfizer Hope to Have Late-Stage Coronavirus Vaccine Results by October

Motley Fool

Flag link:

Moderna gets $1.5B from US for coronavirus vaccine supply

Moderna gets $1.5B from US for coronavirus vaccine supply

BioPharma Dive

Moderna Therapeutics

government contract

Flag link:

Hahn: COVID-19 vaccine decision will be "deliberative"

Hahn: COVID-19 vaccine decision will be "deliberative"

RAPS.org

Flag link:

AstraZeneca bumps up vaccine deal with Brazil to $360M with more doses, licensing rights

AstraZeneca bumps up vaccine deal with Brazil to $360M with more doses, licensing rights

Fierce Pharma

Flag link:

Novavax Ready to Produce Nearly 3 Billion Coronavirus Vaccine Doses (With a Little Help From Friends)

Novavax Ready to Produce Nearly 3 Billion Coronavirus Vaccine Doses (With a Little Help From Friends)

Motley Fool

Flag link:

Putin Says Russian Covid-19 Vaccine Ready To Go January 1, 2021

Putin Says Russian Covid-19 Vaccine Ready To Go January 1, 2021

Forbes

Flag link:

One in Three Americans Would Not Get COVID-19 Vaccine

One in Three Americans Would Not Get COVID-19 Vaccine

Gallup

Flag link:

Pfizer, Moderna and Gilead reputations climb on COVID-19 vaccine and treatment news, according to Harris Poll

Pfizer, Moderna and Gilead reputations climb on COVID-19 vaccine and treatment news, according to Harris Poll

Fierce Pharma

Gilead Sciences

Moderna Therapeutics

Flag link:

Gates Foundation, world's largest vaccine maker to make low-cost COVID-19 vaccine

Gates Foundation, world's largest vaccine maker to make low-cost COVID-19 vaccine

Beckers Hospital Review

Gates Foundation

Flag link:

Pages